×

Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomic ratios

  • US 10,209,240 B2
  • Filed: 12/20/2017
  • Issued: 02/19/2019
  • Est. Priority Date: 11/02/2012
  • Status: Active Grant
First Claim
Patent Images

1. A method of screening the teratogenicity of a test compound, the method comprising:

  • providing a test compound;

    culturing undifferentiated human stem cell-like cells (hSLCs) in the presence of the test compound and in the absence of the test compound, wherein hSLCs are selected from the group consisting of human embryonic stem cells (hESCs), human induced pluripotent (iPS) cells, human embryoid bodies, and hSLC-derived lineage-specific cells;

    determining the fold change in ornithine, or fragment, adduct, deduct or loss thereof, in the culture media of undifferentiated hSLCs cultured in the presence of the test compound in comparison with hSLCs cultured in the absence of the test compound;

    determining the fold change in cystine, or fragment, adduct, deduct or loss thereof, in the culture media of undifferentiated hSLCs cultured in the presence of the test compound in comparison with hSLCs cultured in the absence of the test compound; and

    determining the ratio of the fold change in ornithine, or fragment, adduct, deduct or loss thereof, to the fold change in cystine, or fragment, adduct, deduct or loss thereof, wherein a ratio of less than or equal to 0.88 is indicative of the teratogenicity of the compound, and a ratio of greater than 0.88 is indicative of the non-teratogenicity of the compound.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×